Curative Biotechnology CUBT · USD

Market value

$890.4m

Last close × shares

Volume

1.3k

Shares, 9 Nov 2026

Its shares trade under the ticker CUBT. It has been listed since 11 July 2001. In the fiscal year to 31 December 2016, it reported revenue of $11,091 and a net loss of $17,400. At that date it held total assets of $65,909 and shareholders' equity of −$636,384.

Curative Biotechnology, Inc. engages in the provision of software solutions for the healthcare market. The company is headquartered in Boca Raton, Florida. The company went IPO on 2001-07-11. The firm is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. The company has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. The company is focused on its degenerative eye disease platform. The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage age-related macular degeneration (AMD) disease. Its pipeline products include IMT504, CURB906, Metformin Reformulation, and COVID Vaccine with IMT504 Adjuvant. IMT504 is an immunotherapy for late-stage symptomatic rabies. CURB906 is a humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor.

Figures and description from our data supplier, not checked against the company's own report.

More about Curative Biotechnology →

We have not reported on Curative Biotechnology yet.

Leaves out fees, taxes and financing.

Chart

TradingView

Close and company data

Our data supplier

News

Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.